Innate Competitors
| IPHA Stock | USD 1.70 0.08 4.49% |
Innate Pharma vs Elicio Therapeutics Correlation
Weak diversification
The correlation between Innate Pharma and ELTX is 0.37 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Innate Pharma and ELTX in the same portfolio, assuming nothing else is changed.
Moving against Innate Stock
| 0.57 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.38 | DSGN | Design Therapeutics | PairCorr |
| 0.37 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.35 | 63E | ONWARD MEDICAL BV | PairCorr |
Innate Pharma Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Innate Pharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Innate and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Innate Pharma does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Innate Stock performing well and Innate Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Innate Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CRDF | 4.07 | (0.55) | 0.00 | (0.11) | 0.00 | 9.28 | 45.59 | |||
| RANI | 3.57 | (0.97) | 0.00 | (0.29) | 0.00 | 8.21 | 26.23 | |||
| MIST | 3.22 | 0.09 | 0.02 | 0.19 | 4.42 | 6.15 | 34.31 | |||
| CGEN | 2.94 | 0.24 | 0.02 | (0.28) | 3.21 | 6.57 | 23.25 | |||
| CRBP | 2.62 | (0.50) | 0.00 | (0.51) | 0.00 | 5.95 | 16.04 | |||
| MOLN | 2.51 | 0.00 | (0.02) | 0.09 | 3.26 | 4.73 | 14.54 | |||
| CYBN | 3.09 | (0.05) | 0.00 | 0.16 | 0.00 | 6.03 | 16.13 | |||
| NVCT | 2.74 | 0.60 | 0.22 | 0.55 | 2.37 | 7.20 | 17.53 | |||
| APLT | 7.02 | (2.58) | 0.00 | (1.43) | 0.00 | 10.00 | 83.66 | |||
| ELTX | 3.16 | (0.20) | 0.00 | (0.02) | 0.00 | 6.58 | 22.82 |
Cross Equities Net Income Analysis
Compare Innate Pharma and related stocks such as Cardiff Oncology, Rani Therapeutics, and Milestone Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRDF | (5.4 M) | (2.2 M) | (11.6 M) | (11.8 M) | (14.3 M) | (27.5 M) | (39.2 M) | (24.9 M) | (16.5 M) | (16.4 M) | (19.3 M) | (28.3 M) | (38.7 M) | (41.4 M) | (45.4 M) | (40.9 M) | (38.8 M) |
| RANI | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (26.6 M) | (16.7 M) | (8.3 M) | (30.6 M) | (34 M) | (30 M) | (27 M) | (28.4 M) |
| MIST | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (23.2 M) | (55.2 M) | (50 M) | (42.9 M) | (57.1 M) | (59.7 M) | (41.5 M) | (37.4 M) | (39.2 M) |
| CGEN | (8.1 M) | (12 M) | (13.6 M) | (14.1 M) | (11.1 M) | (20.2 M) | (31.5 M) | (37.1 M) | (22.6 M) | (27.3 M) | (27.3 M) | (32.9 M) | (33.7 M) | (18.8 M) | (14.2 M) | (12.8 M) | (13.4 M) |
| CRBP | (887) | (887) | (887) | (602.4 K) | (2.5 M) | (8.9 M) | (20 M) | (32.4 M) | (55.7 M) | (71.5 M) | (111.3 M) | (45.6 M) | (55.8 M) | (44.6 M) | (40.2 M) | (36.2 M) | (38 M) |
| MOLN | 7.1 M | 7.1 M | 7.1 M | 7.1 M | (2.3 M) | (148.8 K) | (18.6 M) | (25.4 M) | (37 M) | (36.3 M) | (62.8 M) | (63.8 M) | 117.9 M | (62 M) | (54 M) | (48.6 M) | (46.2 M) |
| NVCT | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (10 K) | (12.9 M) | (18.8 M) | (22.3 M) | (19 M) | (17.1 M) | (18 M) |
| APLT | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (16.5 M) | (45.4 M) | (93 M) | (104.6 M) | (82.5 M) | (119.8 M) | (105.6 M) | (95.1 M) | (99.8 M) |
| ELTX | 307.3 K | 307.3 K | 307.3 K | 632.2 K | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (40.7 M) | (80.1 M) | (26.4 M) | (28.2 M) | (35.2 M) | (51.9 M) | (46.7 M) | (49 M) |
Innate Pharma and related stocks such as Cardiff Oncology, Rani Therapeutics, and Milestone Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Innate Pharma financial statement analysis. It represents the amount of money remaining after all of Innate Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Innate Pharma Competitive Analysis
The better you understand Innate Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Innate Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Innate Pharma's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Innate Pharma Competition Performance Charts
Five steps to successful analysis of Innate Pharma Competition
Innate Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Innate Pharma in relation to its competition. Innate Pharma's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Innate Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Innate Pharma's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Innate Pharma, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Innate Pharma position
In addition to having Innate Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Impulse Thematic Idea Now
Impulse
Large corporations operating in retail, broadcasting, energy, airlines and telecom sectors. The Impulse theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Impulse Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Innate Pharma Correlation with its peers. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. Market participants price Innate higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Innate Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.75) | Earnings Share (0.65) | Revenue Per Share | Quarterly Revenue Growth (0.61) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Innate Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.